The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Innovative treatment strategies for multiple myeloma
Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, comments on new developments in treatments for multiple myeloma. Novel immunomodulating agents such as iberdomide and other cereblon E3 ligase modulators (CELMoDs) have shown promising results and could be given in combination with other immunological therapies. In addition, new drugs, including selinexor and melflufen are now available in the relapsed/refractory setting and could potentially be used in earlier lines of treatment. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
